Restart Life Sciences (HEAL) AI Stock Analysis

10 Followers

Restart Life Sciences

(CNQX:HEAL)

Select Model

Rating:46Neutral

Price Target:CAD 0.07▼(-8.00% Downside)

Action:upgraded

Date:11/07/26

Weak financial performance from pre-revenue operations and cash burn is the dominant factor; moderate technical indicators provide limited offset while negative valuation metrics align with early-stage biotech risk.

Positive Factors

Improved 2025 balance sheetThe return to positive equity and modest leverage improves financial flexibility compared with the prior two years. This provides a more stable base for funding operations and may reduce balance-sheet pressure, although the improvement must persist to become a durable strength.

Negative Factors

No recurring revenueThe absence of recurring revenue means the company has not yet demonstrated commercial traction or a dependable customer-funded business model. This limits internal funding capacity, makes future performance highly uncertain, and leaves growth dependent on establishing revenue generation.

Restart Life Sciences (HEAL) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 956.35K
Dividend Yield: ―
Average Volume (3M): 101.47K
Price to Earnings (P/E): -2.0
Beta (1Y): 0.11
Revenue Growth: ―
EPS Growth: -450.88%
Country: Canada
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Restart Life Sciences Business Overview & Revenue Model

Company Description

Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder,...

Restart Life Sciences Financial Statement Overview

Summary

Early-stage biotech with zero revenue, persistent operating losses, and ongoing cash burn, though equity recovered to positive territory and net losses narrowed in recent periods.

Income Statement

35Negative

Balance Sheet

40Negative

Cash Flow

30Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	465.71K	0	0	0	0	0
Gross Profit	-815.18K	0	0	25.41K	-3,792	-4,998
EBITDA	-1.52M	-1.34M	-656.20K	-1.20M	-1.84M	-2.68M
Net Income	-1.50M	-1.39M	224.75K	-1.22M	-3.76M	-2.68M
Balance Sheet
Total Assets	1.90M	1.77M	190.40K	31.06K	296.79K	881.16K
Cash, Cash Equivalents and Short-Term Investments	762.36K	1.65M	169.95K	8,088	266.52K	218.73K
Total Debt	348.35K	245.36K	79.88K	0	0	0
Total Liabilities	578.90K	480.21K	489.47K	841.66K	255.44K	422.06K
Stockholders Equity	1.32M	1.29M	-299.07K	-810.60K	41.34K	459.10K
Cash Flow
Free Cash Flow	-906.33K	-717.22K	-71.77K	-277.53K	-1.44M	-1.95M
Operating Cash Flow	-906.33K	-717.22K	-71.77K	-277.53K	-1.44M	-1.95M
Investing Cash Flow	-944.52K	0	0	0	0	29.64K
Financing Cash Flow	2.40M	2.30M	75.00K	19.10K	1.49M	0

Restart Life Sciences Technical Analysis

Technical Analysis SentimentPositive

Last Price0.07

Price Trends

50DMA0.07Positive

100DMA0.08Negative

200DMA0.09Negative

Market Momentum

MACD-0.00Positive

RSI51.27Neutral

STOCH25.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:HEAL, the sentiment is Positive. The current price of 0.07 is above the 20-day moving average (MA) of 0.07, above the 50-day MA of 0.07, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of -0.00 indicates Positive momentum. The RSI at 51.27 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:HEAL.

Restart Life Sciences Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

TSE:HEAL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TSE:HEAL	46Neutral	CAD 4.69M	-1.96	-170.82%	―	―	-450.88%

* Healthcare Sector Average

Performance Comparison

TSE:HEAL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:HEAL	Restart Life Sciences Corp.	0.07	-0.04	-31.82%
TSE:MYND	Mynd Life Sciences Inc	0.07	0.00	0.00%
TSE:IBO	Universal Ibogaine Inc	0.01	0.00	0.00%
TSE:MBIO	Mindbio Therapeutics Corp.	0.09	-1.17	-93.20%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Restart Life Sciences AI Stock Analysis